Therapeutic Indications and Main Uses

Overt is primarily utilized for the management of specific conditions involving the central nervous system. It is indicated for the treatment of various forms of epilepsy, serving as both a monotherapy and an adjunctive treatment depending on the clinical presentation and the patient's age.

Treatment of Epilepsy

The medication is used to control several types of seizures, including:

• Partial-Onset Seizures: These are seizures that begin in a specific area of the brain. Overt can be used in patients with or without secondary generalization, where the seizure activity eventually spreads to both sides of the brain.
• Myoclonic Seizures: It is indicated for the management of brief, shock-like jerks of a muscle or a group of muscles, typically observed in patients with juvenile myoclonic epilepsy.
• Primary Generalized Tonic-Clonic Seizures: These involve the entire brain from the onset, characterized by muscle stiffening and rhythmic jerking.

Benefits and Clinical Effects

The primary objective of treatment with Overt is to reduce the frequency and severity of seizure activity. By stabilizing electrical activity in the brain, the medication helps to restore a more consistent neurological state.

Neurological Stabilization

Overt works by modulating the release of neurotransmitters. This mechanism helps to prevent the excessive and hypersynchronous firing of neurons that leads to seizures. For patients, this stabilization can lead to extended periods of seizure freedom or a significant reduction in the number of episodes experienced over time.

Impact on Daily Functioning

By providing effective seizure control, the medication aims to support the maintenance of daily activities and improve the predictability of neurological health. Successful management of seizure disorders can contribute to the preservation of cognitive function and the reduction of risks associated with unpredictable seizure events.

Regulatory References

1. Summary of Product Characteristics (SmPC) from the HPRA

Official Eligibility for Overt (Betahistine Dihydrochloride)

Absolute Contraindications Overt must not be used by individuals diagnosed with phaeochromocytoma (a tumor of the adrenal gland) or by patients with a known hypersensitivity (allergy) to betahistine dihydrochloride or any component of the tablet. The medicine is also contraindicated for patients with certain rare hereditary problems, such as galactose intolerance, as listed in the official labeling.

Age- and Population-Based Restrictions The medication is not recommended for use in children and adolescents under 18 years of age. This restriction is due to insufficient data establishing safety and efficacy in the pediatric population. Use is generally indicated for adults. For the elderly, use is permitted, and based on post-marketing data, no dosage adjustment is typically necessary.

Conditional Use and Caution Special caution and patient monitoring are explicitly required for individuals with a history of peptic ulceration or bronchial asthma. Use should also be approached cautiously in cases of severe hypotension. Regarding reproductive health, use during pregnancy should be avoided as a precautionary measure. For breastfeeding women, it is not known whether the drug is excreted in human milk; thus, a decision must be made to discontinue either nursing or Overt therapy.

Interactions with other medicines and products

Overt (Betahistine dihydrochloride) has officially documented interaction patterns based on both metabolic and pharmacodynamic mechanisms, as described in regulatory documentation.

---

Pharmacokinetic Interactions

Interacting Substance/Class	Mechanism & Official Outcome
Monoamine Oxidase Inhibitors (MAOIs)	MAOIs, including selective MAO-B inhibitors like Selegiline, inhibit the metabolism of Overt. This metabolic inhibition is expected to increase the plasma concentration (exposure) of Overt, requiring caution during co-administration.
CYP450 Enzymes	Overt is not expected to cause in vivo inhibition of Cytochrome P450 enzymes based on in vitro data.

---

Pharmacodynamic Interactions

Interacting Substance/Class	Mechanism & Official Outcome
Antihistamines (H1 antagonists)	A theoretical antagonism exists due to Overt's classification as a histamine analogue and the opposing action of H1 antagonists. Co-administration is cautioned against as it may lead to a mutual reduction in efficacy for one or both products.

---

Interaction with Food

Co-administration with food intake only affects the rate of absorption of Overt, causing a reduction in the peak concentration ( C max). Regulatory documents confirm that the total extent of absorption (AUC) remains similar whether Overt is taken in a fed or fasted state.

Overt functions through two core mechanistic domains: modulation of the central vestibular system and enhancement of inner ear microcirculation. The mechanism is centered on the histamine signaling pathways.

---

Modulating the Balance Center via H₃ Receptor Antagonism

This domain covers the drug's primary action on its main molecular target: the Histamine mathbfH3 receptor in the brain's vestibular nuclei. The drug acts as an antagonist (blocker) at these receptors, effectively removing an inhibitory brake on the release of key neurotransmitters (histamine, norepinephrine). This action facilitates the process of neuroplasticity within the vestibular pathway, which accelerates the brain's recalibration to asymmetrical inner ear input, a process known as central vestibular compensation.

---

Regulating Inner Ear Fluid Dynamics

This domain describes the secondary, peripheral effect on the inner ear's vasculature and fluid pressure. The H3 antagonism, combined with a weak H1 agonism, increases the local release of endogenous histamine, resulting in vasodilation and enhanced microvascular blood flow to the cochlea and labyrinth . This improved perfusion is linked to changes in inner ear fluid dynamics and contributes to the reduction of endolymphatic hydrops (fluid pressure imbalance) by promoting fluid reabsorption, which alters balance signal transmission.

Official Administration Guidelines

Overt, which contains the active ingredient betahistine dihydrochloride, is an oral tablet used for long-term management. The use of this medicine follows specific protocols regarding dosing, frequency, and administration conditions.

---

Dosing and Schedule

The total recommended daily dose for adults generally ranges from 24 mg to 48 mg of betahistine. This quantity is typically administered in divided doses, meaning the total daily amount is distributed for intake two or three times daily. The regimen is often initiated with a lower dose, such as 8 mg to 16 mg taken three times daily, and may be adjusted over time according to clinical response, but should not exceed the 48 mg daily maximum.

---

Administration Conditions

Feature	Official Labeled Instruction
Administration Route	Oral, by swallowing the tablet whole with water.
Timing Relative to Meals	Tablets are taken preferably with or immediately after meals. This condition is noted to help alleviate potential mild gastrointestinal discomfort.
Duration of Use	Intended for long-term continuous use. Therapeutic benefit may require several weeks or months of consistent administration before significant reduction in symptom frequency is observed.
Missed Dose Rule	If a dose is missed, the standard procedure is to skip the missed dose and continue with the next scheduled dose at the usual time; double doses should not be taken.

---

Population Use Constraints

The medication is not recommended for use in children or adolescents below the age of 18 due to the absence of sufficient data concerning efficacy and safety in this age group. No dose adjustments are typically necessary for older adults or for patients with hepatic or renal impairment.

Research Evidence / Overview of Studies for Overt

Evidence for Use in Managing Ménière's Disease Symptoms

Research has examined Overt's active ingredient in patients who experience conditions characterized by fluctuating or episodic manifestations, specifically Ménière's disease. These studies included Randomized Controlled Trials (RCTs), where adult participants tracked changes in the frequency and intensity of their spinning dizziness (vertigo) episodes using patient-reported outcomes. Researchers monitored these core outcomes describing episodic or acute changes, as well as other outcomes related to physical discomfort like ringing in the ears (tinnitus) and a feeling of fullness in the affected ear.

Findings describe patterns observed in the studies where, in some analyses, changes in measured outcomes were reported compared to the use of an inactive substance (placebo). However, a large-scale, methodologically rigorous RCT that looked specifically at the rate of vertigo attacks did not report a significant difference between the study treatment and placebo for this primary outcome. The evidence quality varies across studies, and systemic reviews indicate that the overall certainty remains low when drawing conclusions about the drug's effect on vertigo attack frequency versus placebo.

What remains uncertain is the clear and consistent impact of the drug on all aspects of Ménière's disease. Findings related to tinnitus severity or tracking hearing status in the short-term have been mixed or limited. This highlights that research has explored outcomes related to acute episodes but has data for certain groups remain insufficient when attempting to characterize a predictable long-term response across all symptoms.

Research into Vertigo of Other Peripheral Causes

The active ingredient of Overt was evaluated in research that included individuals with other types of vertigo originating from the inner ear, referred to broadly as peripheral vestibular vertigo. These research scenarios often used real-world observational settings evaluating daily-life functioning, where patients tracked how symptoms affected their day-to-day activities. Researchers examined outcomes reflecting daily functioning or activity level, such as patient-reported scores of disability related to dizziness, in addition to tracking the overall severity of the spinning sensation.

In these studies, which included a mix of diagnoses, research highlights changes measured during the study period, including patient-reported outcomes related to functional status over several months of observation. Some studies comparing the active ingredient to other agents reported measurements suggesting different levels of overall symptom change. However, since the research often included multiple vertigo causes, and many were not designed with a placebo control, the evidence is limited in determining a precise, condition-specific effect. The heterogeneity of diagnoses in these studies means that results apply only to the populations studied and contribute to the broader evidence landscape rather than providing a definitive answer for every specific type of peripheral vertigo.

Long-Term Research and Study Follow-Up

The evaluation of any treatment for conditions characterized by fluctuating or episodic manifestations like Ménière's disease requires consistent, long-term observation. Core randomized trials typically monitored patients over intermediate-term periods, such as for several months, with defined assessment periods, but these follow-up durations were limited.

Studies report how symptoms evolved in the observed populations over these defined time intervals. Some open-label, non-controlled studies describe patterns where continued use was observed, and patient-reported symptoms continued to evolve. However, long-term effects are not fully established by the highest quality randomized data, especially concerning the prevention of disease progression or the long-term status of hearing. There is limited information for long-term outcomes regarding the durability of any reported symptomatic changes years after starting treatment.

Evidence in Specific Subgroups

Research has predominantly focused on adult patients diagnosed with Ménière's disease. Specific formal trials to evaluate the active ingredient in pediatric populations (children) have generally not been reported. Similarly, while large observational studies may include older adults, subgroup findings are uncertain or are not consistently published to isolate the effect of treatment in very elderly populations or in those with complex comorbidities.

When researchers examine real-world data, they find that patients who had conditions involving periods of heightened symptoms often also had other chronic health issues. The published research, however, typically reports average outcomes, meaning that the data for certain groups remain insufficient to determine if individuals with significant pre-existing conditions were observed to respond differently to the research treatment.

Understanding the Evidence Consistency and Gaps

The body of research contributes to the broader evidence landscape, but it also highlights areas where certainty remains low. The primary limitation noted by systematic reviews is the variability across studies in terms of methodology, the specific outcomes measured, and how symptom change was defined. This means that a unified picture of research findings is challenging to form.

Furthermore, some of the most rigorous research has explored short-term symptom changes but has not consistently addressed what happens over the course of many years. Comparative evidence is lacking in high-quality trials against other medications for vertigo, making it difficult to fully contextualize the findings. Research is ongoing to provide clearer, more consistent data, particularly regarding the frequency of vertigo attacks and the long-term impact on hearing status.

Key Studies & References Summary of Product Characteristics (SmPC) for Serc (Betahistine Dihydrochloride) - Example from a national health authority/HPRA

Common questions about Overt (FAQ)

Q: Is Overt considered a preventative treatment or an acute treatment?

Regulatory documents describe Overt as being for long-term continuous use and for the management of symptoms of Ménière's disease. This aligns with a chronic management approach, rather than solely for acute relief.

Q: Can Overt be used to treat symptoms other than its main approved condition?

Overt's active ingredient is primarily indicated for the symptoms associated with Ménière's syndrome in official product information. While the ingredient may be evaluated in research for other types of peripheral vertigo, its regulatory approval is typically limited to the formally indicated condition(s).

Q: Is the name "Overt" a brand name or a generic name?

Overt is a brand name (or trade name) given to the drug by the manufacturer. The active ingredient within Overt is called betahistine dihydrochloride, which is the generic name.

Q: Why is Overt available only by prescription?

Overt is legally classified as a prescription-only medicine in many regions. This classification means that the drug must be dispensed only upon authorization from a qualified healthcare practitioner.

Q: What is the expected duration of action or how long does one dose of Overt last?

The mean plasma elimination half-life of the active ingredient, betahistine, is approximately 3 to 4 hours. This information is often considered in the formulation of the prescribed dosage schedule.

Q: Do I need to avoid grapefruit or grapefruit juice while taking Overt?

Official regulatory sources do not list grapefruit or grapefruit juice as a known food interaction or contraindication for Overt. However, regulatory guidance suggests informing a healthcare professional about any specific dietary concerns.

Q: Can Overt be taken with a multivitamin or common mineral supplements?

Regulatory documents generally do not list specific interactions with multivitamins or common mineral supplements. Official guidance emphasizes the importance of informing a doctor about all concurrent medications and supplements.

Q: Do the side effects of Overt usually lessen or go away over time?

Regulatory patient information states that common side effects, such as mild stomach issues or headache, are typically mild and official information indicates they are often temporary or stop over time.

Q: Are there known side effects of Overt related to mood or anxiety?

Regulatory lists of side effects focus on common issues like headache and nausea. Rare or very rare neurological/psychiatric side effects, such as a confusional state, have been reported in post-marketing data.

Q: What should be done if a mild side effect of Overt is experienced?

Regulatory guidance notes that mild stomach problems may be alleviated by taking the dose with food. For side effects that persist or are bothersome, information leaflets typically refer users to consult a doctor or pharmacist.

Q: Does Overt require any routine laboratory tests or monitoring?

Official information indicates that Overt does not require routine laboratory tests (such as regular blood work or kidney function tests). Monitoring typically focuses on the patient's symptoms and vigilance for pre-existing conditions.

Q: Is there information about Overt interacting with over-the-counter pain relievers like ibuprofen or acetaminophen?

Regulatory sources generally do not list specific interactions with common over-the-counter pain relievers such as acetaminophen (paracetamol) or ibuprofen. It is important to inform a healthcare professional about all medicines being taken.

Q: What is the general information about taking Overt and alcohol consumption?

Regulatory patient information advises caution when consuming alcohol while on Overt. This is because alcohol may worsen symptoms related to the underlying condition, such as dizziness or tiredness.

Q: What is the standard half-life of Overt as listed in regulatory documents?

The mean plasma elimination half-life (the time it takes for half the drug to be eliminated from the plasma) of the active ingredient, betahistine, is approximately 3 to 4 hours.

Q: Is it okay to temporarily stop taking Overt without consulting a doctor?

Overt is intended for long-term continuous use for managing chronic symptoms. Regulatory guidance indicates that changes to the treatment regimen should not be made without consulting a healthcare professional.

Q: Are there any general warnings about Overt and driving or operating heavy machinery?

Official regulatory text states Overt is not likely to affect the ability to drive or use tools/machinery. However, the underlying condition (vertigo) can cause dizziness, and regulatory information suggests that individuals experiencing vertigo symptoms should avoid driving or operating hazardous activities.

How to Store and Dispose of Overt?

Storage Category	Official Regulatory Requirements
Temperature & Moisture	Store the tablets at controlled room temperature, typically not above 25 C or 30 C (depending on the product license), and protect from moisture [HPRA SmPC].
Container & Protection	Keep the medicine in the original package (blister/carton) and securely out of the sight and reach of children [Drugs.com Patient Leaflet].
Disposal Instructions	Do not throw away unused or expired tablets in household waste or wastewater. Medicines must be disposed of in accordance with local requirements, typically by returning them to a pharmacist or official collection point [emc SmPC].

Official regulatory documents define the storage profile of Overt by stipulating required temperature limits and mandating environmental protection against moisture. The instructions strictly require that the product remain in its original packaging and include a mandatory statement for child safety. Labeled disposal rules prohibit household waste or wastewater disposal, directing that unused products must be handled by a pharmacist to comply with environmental protection regulations.